ALX Oncology Holdings Inc.
NASDAQ:ALXO
Overview | Financials
Company Name | ALX Oncology Holdings Inc. |
Symbol | ALXO |
Currency | USD |
Price | 1.83 |
Market Cap | 96,519,873 |
Dividend Yield | 0% |
52-week-range | 1.19 - 17.825 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jason W. Lettmann |
Website | https://www.alxoncology.com |
An error occurred while fetching data.
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD